AIM IMMUNOTECH INC
AIMNYSE AMERICANTrading Snapshot
- Day Range
- $0.17 – $0.17
- 52-Week Range
- $0.15 – $2.54
- Volume (shares)
- 168,433
- Avg Volume (shares)
- —
- Shares Outstanding
- 39.9M
- Next Earnings
- 2026-11-16
Fundamentals Snapshot
- Annual Revenue
- $88,000
- Last Q Revenue
- $26,000
- P/E Ratio
- -0.0
- P/S Ratio
- 69.3x
- EPS (TTM)
- $-0.83
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +96.1%
AIM IMMUNOTECH INC
AIM
StockOtter · stockotter.spaceAbout AIM IMMUNOTECH INC
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
CEO interview explores Ampligen's potential to extend survival and improve quality of life as AIM advances toward pivotal development
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential
OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage of the antiviral potential of Ampligen® (rintatolimod), the Company
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
Recent biotech media features focus on Ampligen's potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program Recent biotech media features focus on A
Ionic Rare Earths targets AIM listing as Belfast magnet recycling strategy gathers pace
Ionic Rare Earths Ltd (ASX:IXR, OTC:IXRRF) is advancing plans to list its shares on London's AIM market in the fourth quarter of 2026 as it builds its UK presence and progresses commercialisation of its rare earth magnet
AIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones
Ondine Biomedical pauses trading to raise fresh investment after positive phase III result
Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the developer of light-activated nasal disinfection for hospital patients, has suspended trading in its shares while it raises new investment to capitalise on its clinical and